Lannett Company, Inc. LCI
Apr 19, 2023, 3:58 PM EDT
52-week range unavailable
- Market cap
- 7.38M
- Revenue (ttm)
- 308.52M
- Profit margin
- -62.40%
- Shares out
- 10.77M
- Forward P/E
- -0.13
- Volume
- 280.66K
- Open
- 0.65
- Previous close
- 0.6855
- Day's range
- 0.6501 – 0.7196
- Beta
- 0.95
- Analysts
- Hold
- Price target
- 4.00 (+483.5%)
- Earnings date
- May 3, 2023
3M -2.1320 (-98.70%)
Key statistics
- Enterprise value
- 586.34M
- PEG ratio
- 0.00
- Price / sales
- 0.02
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -6.50%
- Free cash flow
- 19.33M
- Total cash
- 55.85M
- Total debt
- 635.37M
- Return on equity
- 0.00%
- Short % of float
- 13.28%
- 50-day average
- 1.30
- 200-day average
- 2.00
Analyst view
Consensus: hold
- Strong buy0
- Buy4
- Hold3
- Sell0
- Strong sell0
Next earnings
May 3, 2023
Expected May 3, 2023. Consensus EPS estimate -1.56.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 3, 2023 | Mar 1, 2023 | -1.56 | — | — | — |
| Feb 1, 2023 | Dec 1, 2022 | -1.64 | — | — | — |
| Nov 2, 2022 | Sep 1, 2022 | -1.84 | — | — | — |
| Aug 24, 2022 | Jun 1, 2022 | -1.84 | — | — | — |
| May 4, 2022 | Mar 1, 2022 | -1.72 | — | — | — |
| Feb 3, 2022 | Dec 1, 2021 | -1.28 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 31, 2021 | Roth Capital | main | — | Neutral |
| Jun 10, 2021 | Roth Capital | main | — | Neutral |
| Sep 18, 2019 | SunTrust Robinson Humphrey | main | — | Hold |
| Aug 29, 2019 | SunTrust Robinson Humphrey | main | — | Hold |
| Mar 20, 2019 | SunTrust Robinson Humphrey | init | — | Hold |
| Aug 21, 2018 | BMO Capital | main | Market Perform | Market Perform |
About Lannett Company, Inc.
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's product portfolio includes Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, and Verapamil SR tablets, as well as Numbrino nasal solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- lannett.com
News
LCI Board Determines That the Unsolicited, Non-Binding Proposal From Monomoy Capital Partners Does Not Constitute a Superior Proposal
Patrick Industries, Inc. Reaffirms Merger Agreement with LCI Industries
LCI Industries Confirms Receipt of Unsolicited, Non-Binding Proposal from Monomoy Capital Partners
LCI Industries Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LCI Industries - LCII
LCI Industries Third Quarter 2026 Conference Call Scheduled for November 5, 2026, at 8:30 a.m. ET
LCI Industries Q2 Earnings Call Highlights
LCI Industries Declares Quarterly Cash Dividend
LCI Industries Second Quarter 2026 Conference Call Scheduled for August 5, 2026, at 8:30 a.m. ET
LCI Industries Appoints Robert Hureau to Board of Directors
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)
Your note
Sign in to keep a note on LCI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABT JOHN M | Officer | Purchase | Feb 9, 2022 | 128,815 |
| CHAPMAN JOHN C | Director | Purchase | Nov 16, 2022 | 174,324 |
| CREW TIMOTHY C | Chief Executive Officer | Purchase | Nov 9, 2022 | 604,291 |
| DRABIK DAVID A | Director | Stock Award(Grant) | Aug 30, 2021 | 108,332 |
| EHLINGER ROBERT | Former | Stock Award(Grant) | Dec 2, 2021 | 105,491 |
| FARBER JEFFREY | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 16, 2022 | 2,152,450 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Telemus Capital, LLC | 4.47% | 1,927,199 | 1.32M | Mar 30, 2023 |
| Renaissance Technologies, LLC | 1.13% | 487,620 | 334.26K | Dec 30, 2022 |
| Shaw D.E. & Co., Inc. | 0.70% | 302,532 | 207.38K | Dec 30, 2022 |
| Vanguard Group, Inc. (The) | 0.43% | 185,455 | 127.13K | Dec 30, 2022 |
| Staley Capital Advisers, Inc. | 0.36% | 153,786 | 105.42K | Dec 30, 2022 |
| Blackrock Inc. | 0.33% | 143,421 | 98.31K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.29% | 122,936 | 84.27K | Sep 29, 2022 |
| Invesco ETF Tr-Invesco FTSE RAFI US 1500 Small-Mid ETF | 0.23% | 97,190 | 66.62K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.13% | 57,037 | 39.10K | Nov 29, 2022 |
| Vanguard Total Stock Market Index Fund | 0.11% | 46,314 | 31.75K | Sep 29, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.10% | 41,475 | 28.43K | Sep 29, 2022 |
| Bridge Builder Tr-Bridge Builder Small/Mid Cap Value Fd | 0.03% | 14,425 | 9.89K | Sep 29, 2022 |
